# Trade Mark Journal No.2026/001 2 January 2026

## WO0000001878665 (5,9,42)

Office of origin: United States of America

Date of International Registration:4 April 2025
Date of designation in the UK: 4 April 2025

International priority date claimed: 4 October 2024 (United States of America) (98785571)

Class 5
  Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders.
Class 9
  Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics.
Class 42
  Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; scientific research, namely, research and analysis services for the design and characterization of chemical and biologic therapeutic products; research services in the fields of genomic, transcriptomic, and proteomic analysis; genomic and proteomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; DNA analysis and sequencing services for scientific and research purposes; research, development and consultancy in the field of genomics and proteomics; medical research, namely, compiling data for research purposes in the field of genomics and proteomics; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics.

EXPEDITION MEDICINES, INC.

Representative: Kilburn & Strode LLP, Lacon London, 84 Theobalds Road London WC1X 8NL UNITED KINGDOM